Diane Baniewicz

1.3k total citations
16 papers, 495 citations indexed

About

Diane Baniewicz is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Genetics. According to data from OpenAlex, Diane Baniewicz has authored 16 papers receiving a total of 495 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Public Health, Environmental and Occupational Health and 3 papers in Genetics. Recurrent topics in Diane Baniewicz's work include CAR-T cell therapy research (12 papers), Acute Lymphoblastic Leukemia research (7 papers) and Virus-based gene therapy research (3 papers). Diane Baniewicz is often cited by papers focused on CAR-T cell therapy research (12 papers), Acute Lymphoblastic Leukemia research (7 papers) and Virus-based gene therapy research (3 papers). Diane Baniewicz collaborates with scholars based in United States and Canada. Diane Baniewicz's co-authors include Colleen Callahan, Stephan A. Grupp, Shannon L. Maude, Amanda M. DiNofia, Carl H. June, David T. Teachey, George Hucks, Simon F. Lacey, Alix E. Seif and Vanessa Gonzalez and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biology of Blood and Marrow Transplantation.

In The Last Decade

Diane Baniewicz

16 papers receiving 491 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diane Baniewicz United States 12 388 105 97 91 87 16 495
Houston Holmes United States 12 319 0.8× 82 0.8× 69 0.7× 88 1.0× 119 1.4× 39 540
Christine L. Phillips United States 11 247 0.6× 136 1.3× 66 0.7× 103 1.1× 32 0.4× 38 381
Alessandro Crotta United States 7 273 0.7× 39 0.4× 43 0.4× 48 0.5× 55 0.6× 26 369
Florence Morin France 15 236 0.6× 23 0.2× 66 0.7× 100 1.1× 174 2.0× 25 499
Adam J. Lamble United States 12 282 0.7× 126 1.2× 57 0.6× 159 1.7× 147 1.7× 54 548
Ira L. Kraft United States 9 130 0.3× 35 0.3× 68 0.7× 77 0.8× 43 0.5× 19 295
Sajad Khazal United States 10 138 0.4× 122 1.2× 37 0.4× 66 0.7× 42 0.5× 33 322
Marie-Elisabeth Goebeler Germany 6 324 0.8× 74 0.7× 21 0.2× 40 0.4× 110 1.3× 7 392
Xiaoqian Liang China 6 243 0.6× 27 0.3× 68 0.7× 117 1.3× 98 1.1× 8 334
Eugenio Galli Italy 9 176 0.5× 22 0.2× 50 0.5× 37 0.4× 49 0.6× 43 280

Countries citing papers authored by Diane Baniewicz

Since Specialization
Citations

This map shows the geographic impact of Diane Baniewicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diane Baniewicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diane Baniewicz more than expected).

Fields of papers citing papers by Diane Baniewicz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diane Baniewicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diane Baniewicz. The network helps show where Diane Baniewicz may publish in the future.

Co-authorship network of co-authors of Diane Baniewicz

This figure shows the co-authorship network connecting the top 25 collaborators of Diane Baniewicz. A scholar is included among the top collaborators of Diane Baniewicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diane Baniewicz. Diane Baniewicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
DiNofia, Amanda M., Yimei Li, Susan R. Rheingold, et al.. (2024). Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy. Blood Advances. 9(2). 354–359. 1 indexed citations
2.
Myers, Regina M., Yimei Li, Allison Barz Leahy, et al.. (2021). Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Blood. 138(Supplement 1). 474–474. 11 indexed citations
3.
Leahy, Allison Barz, Haley Newman, Yimei Li, et al.. (2021). CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. The Lancet Haematology. 8(10). e711–e722. 77 indexed citations
4.
Leahy, Allison Barz, Yimei Li, Hongyan Liu, et al.. (2021). Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood. 139(14). 2173–2185. 61 indexed citations
5.
6.
Myers, Regina M., Stephan Kadauke, Yimei Li, et al.. (2020). Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL). Biology of Blood and Marrow Transplantation. 26(3). S39–S39. 14 indexed citations
7.
Kadauke, Stephan, Shannon L. Maude, Whitney L. Gladney, et al.. (2019). Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019). Cytotherapy. 21(5). e2–e3. 12 indexed citations
8.
Leahy, Allison Barz, Regina M. Myers, Amanda M. DiNofia, et al.. (2019). Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy. Blood. 134(Supplement_1). 1464–1464. 9 indexed citations
9.
Phillips, Charles, Emily Foster, Diane Baniewicz, et al.. (2018). Implementation of an Automated Pediatric Malnutrition Screen Using Anthropometric Measurements in the Electronic Health Record. Journal of the Academy of Nutrition and Dietetics. 119(8). 1243–1249. 9 indexed citations
10.
Li, Amanda M., George Hucks, Amanda M. DiNofia, et al.. (2018). Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood. 132(Supplement 1). 556–556. 121 indexed citations
11.
Callahan, Colleen, Diane Baniewicz, & Beth Ely. (2017). CAR T-Cell Therapy: Pediatric Patients With Relapsed and Refractory Acute Lymphoblastic Leukemia. Clinical journal of oncology nursing. 21(2). 22–28. 11 indexed citations
12.
Baniewicz, Diane, et al.. (2017). Cancer Immunotherapy: An Evidence-Based Overview and Implications for Practice. Clinical journal of oncology nursing. 21(2). 13–21. 17 indexed citations
13.
Wiley, Kathleen E., et al.. (2017). Immunotherapy Administration: Oncology Nursing Society Recommendations. Clinical journal of oncology nursing. 21(2). 5–7. 11 indexed citations
14.
Talekar, Mala K., Shannon L. Maude, George Hucks, et al.. (2017). Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology. 35(15_suppl). 10507–10507. 15 indexed citations
15.
Maude, Shannon L., George Hucks, Alix E. Seif, et al.. (2017). The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology. 35(15_suppl). 103–103. 79 indexed citations
16.
Johnson, Kelsey E., et al.. (2011). Safety and efficacy of tandem 131I‐metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatric Blood & Cancer. 57(7). 1124–1129. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Houston Holmes Breakdown of academic impact, for papers by Christine L. Phillips Breakdown of academic impact, for papers by Alessandro Crotta Breakdown of academic impact, for papers by Florence Morin Breakdown of academic impact, for papers by Adam J. Lamble Breakdown of academic impact, for papers by Ira L. Kraft Breakdown of academic impact, for papers by Sajad Khazal Breakdown of academic impact, for papers by Marie-Elisabeth Goebeler Breakdown of academic impact, for papers by Xiaoqian Liang Breakdown of academic impact, for papers by Eugenio Galli
Rankless by CCL
2026